share_log

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

康泰尔费茨杰拉重申对adma biologics的超配评级,维持20美元的目标股价
Benzinga ·  09/20 11:10  · 评级/大行评级

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:ADMA) with a Overweight and maintains $20 price target.

Cantor Fitzgerald分析师Kristen Kluska重申了adma biologics(纳斯达克:ADMA)的超重,并维持了20美元的目标价格。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发